id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321311-v2i1caug	Weller, Michael	How we treat patients with brain tumour during the COVID-19 pandemic	2020-05-13		.txt	text/plain	2744	119	39	► Weigh benefit versus risk of alkylating agent chemotherapy in patients with gliomas lacking MGMT promoter methylation, notably patients with recurrent disease, reduced performance status or in advanced age. Further, we should prudently weigh risk and benefit of systemic pharmacotherapy in all disease areas where there is little or no evidence for pharmacotherapy at all, not only in meningioma or ependymoma in adults but also in recurrent glioblastoma, where no intervention except nitrosoureas in patients with tumours with O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation is likely to confer meaningful disease control. Essentially, the same holds true for phase III trials; however, clinical trials evaluating novel treatments that are associated with immunosuppression raise ethical concerns: randomising in the current situation against a standard of care indicates that the benefit of the new intervention is uncertain, but the perceived risk of increased sensitivity to infection would seem to make it prohibitory to place patients on such trials.	./cache/cord-321311-v2i1caug.txt	./txt/cord-321311-v2i1caug.txt